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Abstract 
This paper describes the preparation and submission of the original registration dossier1 for 
the East Coast fever vaccine ECF ITM ‘Muguga cocktail’ in Kenya, Tanzania, Uganda and 
Malawi between 2007and 2009.  The process faced a series of challenges in that the ‘vaccine’ 
unconventionally comprises a formulation of three stocks of the live virulent Theileria parva 
parasite administered together with a long-acting formulation of oxytetracycline.  Only two 
batches had been manufactured and the dossier was based on the first, FAO-1.  Since there 
were no official guidelines to follow for the relevant countries the dossier was constructed 
using the official European Union format and guidelines, following the universal principles of 
quality, safety and efficacy.  Specific protocols (SOPs) were prepared to describe the 
production process.  There was a complete lack of specifically designed clinical studies so the 
published and grey literature were searched for evidence to support safety and efficacy and 
these were used for the relevant sections of the dossier.  Registrations were granted in three 
of the four countries in 2008-2009. 
 
Introduction 
East Coast fever (ECF) caused by the apicomplexan parasite Theileria parva (Theiler, 1912) 
and transmitted by the brown ear tick Rhipicephalus appendiculatus is a fatal disease of cattle 
in eastern and southern Africa (see recent review by Nene et al., 2016). Along with other tick-
borne diseases ECF poses a severe constraint to livestock production in sub-Saharan Africa.  
Control has relied mostly on regular acaricide treatment (Dolan, 1999) and anti–theilerial drugs 
(McHardy, 1989) but no effective conventional vaccine has yet been developed, largely due 
to the lack of a complete understanding of the necessary immune mechanisms and how to 
stimulate them (Morrison and McKeever, 2006; Nene et al., 2016).  An unconventional 
vaccination procedure, known as the Infection and Treatment Method (ITM) was developed in 
 
1 This paper is a description of the original ECF ITM dossier submitted for first registrations in East 
Africa in 2008-2009 and how it was assembled. This together with the draft SPC in Appendix 1 have 
been superseded since that time. 
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the 1970’s (see for example Radley et al. 1975a; b; c).  The procedure relies on infection of 
animals with a potentially lethal dose of the live T. parva sporozoites with concurrent treatment 
with long-acting oxytetracycline to control clinical symptoms.  Thus treated, animals apparently 
acquire life-long immunity to subsequent disease (see review by Morrison and McKeever, 
2006). 
 
It became evident during development of ITM that immunization with one isolate of the parasite 
did not necessarily confer immunity to challenge with other known isolates.    However, an 
ITM formulation based on three different stocks of parasite conferred immunity to challenge 
with several heterologous stocks (Radley et al.,1975c).  The three stocks (Muguga, Kiambu 5 
and Serengeti transformed) are known collectively as the Muguga cocktail, which has been 
used to immunize cattle across broad areas of East Africa (di Giulio et al., 2009).  However 
other monovalent stabilates e.g. Chitongo, Katete and Marikebuni have been used in some 
regions with varying degrees of success (P. Spooner, personal communication). 
 
Although ECF-ITM has been available for almost three decades, its implementation has been 
inconsistent due to various reasons.  First, the complexity of manufacturing the vaccine 
stabilate raised doubts as to whether consistent, commercial-scale batches could be 
produced.  Such batches have been produced in recent years (Patel et al., 2016).  Secondly 
there were epidemiological concerns that the Muguga cocktail would not induce protection 
against field strains found in all geographical situations.   Third, as immunization with live 
parasites can result in a persistently infected or carrier animals, the possibility exists for the 
vaccine strains to be introduced into areas previously free of them (de Castro,1997; Berkvens 
et al., 1998; de Castro et al., 1998; McKeever, 2008).  Fourth, there are significant logistical 
challenges in distribution of a vaccine which requires storage in liquid nitrogen until 
administration into target animals.  Fifth, the product has not been taken up by a private 
commercial organisation, which would be required to maintain sustainable distribution 
channels.  Finally, there was the, as yet unfulfilled, promise of a more conventional, subunit 
vaccine which, in theory at least, is easier to manufacture and deliver (P. Spooner personal 
communication). The institutional history that has formed the backdrop to this fascinating story 
was recently documented by Perry (2016). 
 
In 1996, the International Livestock Research Institute (ILRI) addressed the first issue above 
and produced two commercial scale batches of the Muguga cocktail, known as FAO-1 and 
FAO-2.  In total, about 660,000 doses were manufactured and distributed on a fully 
commercial basis.  The product was not formally registered but its use was allowed by special 
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sanction of the Directors of Veterinary Services in the respective countries.  By 2006, almost 
all of the vaccine had been distributed, indicating, that despite the concerns listed above, and 
the relatively high retail price of US$ 8-12 per dose, there was a demand for the product.  A 
meeting of stakeholders was organised in Nairobi in February 2007 by AU-IBAR where several 
key points were agreed at that meeting.  Amongst these were that ILRI would produce a new 
batch of 1 million doses and that the newly formed GALVmed, a public private partnership and 
alliance, would fund production of a second batch of 500,000 doses subject to the condition 
that there was formal establishment of quality standards for the product in the form of a 
registration dossier and there should be formal product registration in four user countries - 
Kenya, Tanzania, Uganda and Malawi.  Additionally, one or more commercial production sites 
should be established, for which the dossier could also act as a technology transfer and 
training manual.  Subsequently this was selected as the Centre for Ticks and Tick Borne 
Disease (CTTBD) in Lilongwe, Malawi.  
 
The development of the registration dossier presented several challenges, given the unique 
nature of the vaccine and the varying registration procedures in each of the user countries. 
There were very few formal documents on which to base the dossier particularly for the Quality 
(manufacturing) section.  The manufacturing procedure developed by ILRI was largely based 
on research methodology with limited cognizance of regulatory processes and requirements.  
Similarly, there were no established, dedicated clinical study designs to assess either product 
safety or efficacy, resulting in significant deviation from normally accepted studies. Lastly there 
was generally a poor knowledge regarding the regulatory systems for veterinary vaccines in 
the target countries of Kenya, Tanzania, Malawi and Uganda. 
   
This paper documents the approach used to develop the dossier, how each of the unique 
challenges was addressed and presents an outline of the final registration dossier itself.  
 
Design of the dossier  
International registration of medicines (including veterinary medicines) universally relies on 
the principles of product quality, safety and efficacy.  For the ITM vaccine, it was decided to 
develop a registration dossier that could be used, either in full or its modular parts as 
necessary by any national regulatory authority to construct a document that would meet 
individual national requirements. The format for a European registration dossier was selected, 
(EudraLex - Volume 6 - Notice to applicants and regulatory guidelines for medicinal products 
for veterinary use  https://ec.europa.eu/health/documents/eudralex/vol-6_en), as it was 
considered that this would most likely include all necessary requirements.  However the 
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dossier was prepared in the knowledge that the ITM vaccine is an unusual if not unique product 
in veterinary medicine and was thus written with fitness for purpose always in mind. 
 
Structure of the dossier 
The dossier was structured approximately in line with the European Notice to Applicants with 
the parts shown in Table 1. 
 
Table 1.  Structure of the ECF ITM registration dossier 
 
Section Content  
Part 1 Introduction and summary of product characteristics 
Part 2 Quality: manufacturing and control 
Expert report (DACS) on quality section 
Parts 3 and 4 Safety and efficacy 
Expert report (DACS) on safety and efficacy 
Part 5 Appendices 
Standard operating procedures 
Documentation on constituents e.g. MSDS 
Batch production record 
 
The preparation of the dossier is described below noting just the critical features.   
 
Part 1. The summary of product characteristics (SPC; see Appendix 1) 
The SPC (also known as the Data Sheet) was drafted initially in order to ensure clarity and 
alignment on the exact specifications (sometimes referred to as the product profile) of the 
product that was being produced and how it should be used.  The SPC is based essentially 
on the data collected during development of the product.  The main features of the SPC are 
the description of the composition, presentation, indications, contra-indications, storage, 
handling and administration and precautions. 
 
Part 2.  Quality (manufacture and quality control) 
In outline, the Quality section includes the qualitative and quantitative composition of the 
product, a description of the manufacturing method, quality control of starting materials, control 
tests at both intermediate and final product stages, stability and further information on batch 
to batch consistency.  These sections are shown in Table 2. 
 
The manufacturing procedure including control tests was described specifically for batch FAO-
1 and some details included for FAO-2 where these differed significantly.  A description of the 
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manufacture of the next batch named ITM ECF MC ILRI 08 has recently been published by 
Patel et al. (2016).  In essence the principles are the same as used for the earlier batches 
although certain modifications were made to improve the process and these are described in 
that paper.  Thus the manufacturing process will not be described again here.  
 
Table 2. Part 2 of the dossier. Chemical, pharmaceutical and biological / 
microbiological information 
 
A Qualitative and quantitative particulars of 
the constituents 
Active ingredient details, excipients, usual 
terminology (PhEur etc.), quantitative 
amounts of all actives and excipients 
B Description of the manufacturing method Premises, methodology, validation 
C Control of starting materials Provenance and QC tests on starting 
materials 
Packaging and closures 
TSE compliance 
D Control tests at intermediate stages QC tests  
E Control tests on finished product Specifications, compliance with 
specification. 
Safety tests e.g. contaminants endotoxins 
etc. 
F Stability Shelf life of active, product both in storage 
and in-use 
G Further information Batch to batch consistency 
 
It should be noted that this section of a registration dossier is extremely detailed and can be 
somewhat repetitive. Thus in the interests of brevity what follows is just a summarised version 
of the salient features. 
 
A. Constituents 
In addition to the qualitative challenges indicated above for Section 1, the quantitative aspects 
of the composition also required a unique approach.  The sporozoite preparation is essentially 
a semi-purified homogenate of ticks harvested from cattle infected with one of the three 
component stabilates.  One of the major aims of the manufacturing process is to ensure that 
the final vaccine stabilate comprises equal numbers of sporozoites from the three stabilates.  
As the level of parasitaemia in infected cattle can vary considerably (Patel et al., 2016), the 
most direct way of enumerating the numbers of sporozoites is to determine the mean number 
of infected acini (salivary gland cells) in the tick batches, and pool the batches accordingly.  
This does not account for differences in the number of sporozoites in each acinus, nor does it 
allow for loss or death of sporozoites during the remainder of the manufacturing process.  To 
address this, the dossier provided the final concentration of infected acini in the undiluted 
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stabilate and acknowledged that, as losses could be expected during manufacture, the final 
recommended dose relied on subsequent in vivo testing of the stabilate in cattle.  
 
B and C. Manufacturing method and starting materials 
For the dossier, the manufacturing procedure including control tests was described specifically 
for batch FAO-1 and some details included for FAO-2 where these differed significantly.  A 
detailed description of the manufacture of the subsequent batch named ITM ECF MC ILRI 08 
has recently been published by Patel et al. (2015) and is shown in outline in Figure 1.  In 
essence the principles are the same as used for the earlier batches although certain 
modifications were made to improve the process and these are described in that paper. 
 
Figure 1.  Summary of the ECF ITM Muguga cocktail production process 
 
 
 
The procedure is briefly described here.  Production cattle were inoculated with known doses 
of the three seed stabilates. After 12 days, uninfected nymphal R. appendiculatus ticks were 
placed onto the backs of the cattle (approximately 36,000 per animal).  Engorged ticks 
dropping off the cattle were collected and subsequently fed on rabbits for 4 days to allow tick 
maturation.  The salivary glands were removed from a sample of the ticks to estimate the 
number of infected acini per tick.  Calculated aliquots of ticks were ground and homogenized 
and suspended in cryoprotectant medium.  The supernatant containing the sporozoites 
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transferred into 0.5 ml artificial insemination straws which were then frozen by a stepwise 
process in liquid nitrogen.  Each batch was then tested for infectivity followed by a safety and 
dose determination study before release for field evaluation and sale.  A comprehensive 
record of all production processes is kept for each batch.  The batch production record for 
FAO-1 was produced as part of the original dossier. 
 
Two items which required specific attention were the use of live starting materials in the form 
of cattle, ticks and rabbits, and the need for specialized tick facilities and associated expertise.  
Of uppermost concern for the live starting materials was that they were free of extraneous 
pathogens to prevent the contamination of the final stabilate.  Detailed protocols were provided 
to attain this.  These included a description of the preferred source of the material (cattle – 
from areas unsuited to tick-borne infections; ticks and rabbits from closed, characterised 
laboratory colonies), and detailed procedures for screening for common pathogens.  It was 
recognized that the screening could not cover every infectious agent potentially present on 
the cattle, and additional reliance was placed on the absence of untoward clinical signs in the 
animals used in the final testing of the stabilate, as described below. 
     
The production and maintenance of the ticks used in the manufacture requires both expert 
knowledge in the biology of ticks, and equipment including dedicated incubators, dissecting 
apparatus and cattle holding facilities.  ILRI had maintained a tick unit for several decades, 
which, although primarily established for research purposes, met all the requirements for the 
manufacture of the vaccine. 
 
D.  In-process Quality Control tests 
Most of the tests described in this section comprised clinical and parasitological assessments 
of the production cattle following infection, to ensure adequate parasitaemias were attained, 
no extraneous agents were present and that the welfare of the cattle was monitored.    
 
E. Quality Control tests on the finished product 
The primary test to ascertain the fitness of the final product was the infection and challenge 
test described in the next section.  Additional aspects which needed to be addressed and for 
which there was little information were the shelf life of the vaccine and its stability during use.   
The effective shelf life of the vaccine, essentially maintenance of the viability of the sporozoites 
stored in liquid nitrogen, had never been formally evaluated.  Evidence for the longevity was 
therefore sought from field reports, in particular those concerning the FAO batches which had 
been used over a 10-year period at the time this dossier was prepared in 2008.  The evidence 
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from the field was that they were still performing well, and three references were cited to 
support this. 
 
1. Assessment of FAO-1 after storage for 2.5 years at the CTTBD, Lilongwe, Malawi, 
demonstrated that the infectivity of the ILRI VS had been maintained at a similar level as 
at initial storage (Anon, 1999a). 
2. Results from immunisations in the Narok district of Kenya, with vaccine stabilate (VS) that 
had been stored for over 7 years showed it to be safe, with protection of cattle against ECF 
in pastoral systems (Turasha, 2005). 
3. Immunisations with a live trivalent East Coast fever (ECF) vaccine in northern Tanzania, 
between 2000 and 2004, demonstrated a “robust and effective ECF control method”. The 
vaccine stabilate used had been stored for 4-8 years (Lynen et al., 2005). 
4.  In addition, ILRI undertook infectivity tests with the stabilates used in 1996 with similar 
     results. 
 
The Anon (1999a) reference above provides the best experimental evidence that the VS 
retains its potency for at least 2.5 years.  The reports of Turasha (2005) and Lynen et al. 
(2005) are more anecdotal in nature but if there had been evidence of either safety or efficacy 
problems in the field, then these would no doubt have been reported in these publications.  
Based on experience of preservation of other biological materials in liquid nitrogen, it would 
be expected that VS stability would be maintained for many years. 
 
For stability during use, one report indicated that stabilates may be diluted and stored on ice 
for up to 6 hours and used successfully to immunise cattle (Marcotty et al., 2001). These 
immunisations were carried out under optimal conditions and it is considered that the sub-
optimal field conditions may considerably shorten this effective period (Spooner, 2004). From 
this, it was clear that immunisations should be carried out as soon as possible after vaccine 
stabilate thawing and dilution, with the diluted stabilate stored on ice in a cooler box during 
immunisations. In practice there are likely to be delays in immunisations in the field and cattle 
should therefore be mustered in advance to reduce these. The latter applies particularly to 
small holder farms.  The dossier included a recommendation that cattle are immunised within 
2 hours of vaccine stabilate thawing and within a maximum period of 4 hours under optimal 
storage conditions following dilution of the stabilate. 
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Parts 3 and 4. Safety and Efficacy 
 
In a conventional European registration dossier, which had been selected as the template for 
present purposes, it is usual to present safety and efficacy as separate sections.  However, 
for the ITM vaccine, the clinical evidence available to be used as the data package had evolved 
as a series of individual scientific studies without any specific regulatory pathway in mind and 
many of the studies were carried out simultaneously to address both safety and efficacy. 
Therefore for the purposes of the dossier it was decided that the two issues would be 
presented together in a combined section (i.e. Parts 3 & 4; see EudraLex - Volume 6 - Notice 
to applicants and regulatory guidelines for medicinal products for veterinary use. 
https://ec.europa.eu/health/documents/eudralex/vol-6_en 
 
In regulatory terms, Safety can be defined as a lack of local or systemic reactions and in 
statutory tests usually involves daily observations for a 14-day period post-vaccination.  
Vaccine Efficacy can be defined as a significant improvement in clinical signs, infection or 
transmission compared to unvaccinated controls in a series of different tests.  The major sub-
headings for Safety and Efficacy in a European dossier are shown in Table 3. 
 
 
Table 3.  The major safety and efficacy parameters to be addressed in vaccine registration 
 
Safety / efficacy 
parameter 
 
Specific considerations 
Safety 
 
 
Single dose, Repeated dose, Overdose 
Live vaccines – reversion, shed and spread, dissemination 
Field safety 
Pregnancy and lactation 
Environmental safety 
User safety 
Efficacy Experimental challenge 
Immunogenicity (usually based on seroconversion) 
Dose determination 
Onset of immunity 
Duration of immunity 
Field efficacy 
Other Safety and efficacy of oxytetracycline LA 
Economic benefit / acceptance 
 
 
The available evidence for Safety and Efficacy was reviewed under these headings as 
considered relevant and comprised previously published reports and data sheets from the 
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testing of previous batches. Unless otherwise stated the studies on finished product were 
conducted with batch FAO-1.  These were included in the dossier and are listed in Table 4.  In 
addition, the relevance of each report to Safety or Efficacy or both is shown in Table 5.  A 
benefit risk assessment was also included at the end of the dossier.  
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Table 4.   2List of reports used in the Safety and Efficacy section  
(the individual reports / publications were allocated a number SE for easy reference) 
 
Report 
number 
 
Report title Reference 
SE1 Determining a safe and protective immunizing dose for the FAO-1 Theileria parva composite stabilate for use in 
field vaccinations against East Coast fever. 
 
Mutugi et al. (1997) 
SE2 FAO-1 composite stabilate.  Evaluation of efficacy at 1:80 and 1:100 dilutions and treatment with 30% 
oxytetracycline. 
 
Anon (1998) 
SE3 FAO-1-2 composite stabilate.  Evaluation of efficacy at 1:80 direct dilution and treatment with 30% 
oxytetracycline. 
 
Anon (1999b) 
SE4 Titration of the FAO-1 stabilate ILRI (1996) 
 
SE5 The persistence of component Theileria parva stocks in cattle immunized with the ‘Muguga cocktail’ live vaccine 
against east Coast fever in Uganda. 
 
Oura at al. (2004) 
SE6 Theileria parva live vaccination: parasite transmission and heterologous challenge in the field. 
 
Oura et al. (2007). 
SE7 An outbreak of East Coast fever on the Comoros: A consequence of the import of immunised cattle from 
Tanzania? 
 
De Deken et al. (2007). 
SE8 Infectivity / viability test of FAO-1 stabilate after 2½ years storage at CTTBD, Lilongwe, Malawi. 
 
Anon (1999a) 
SE9 Efficacy of East Coast fever (ECF) vaccine on improved and indigenous cattle in Tanzania. 
 
Magwisha et al. 
SE10 Applying ITM immunisation in Tanzania using the FAO-1 vaccine batch (1998-2007). Anon (2007). 
 
2 Some of these reports are not available in the scientific press.  Copies can be obtained from the first author A. R. Peters (andy.peters@ed.ac.uk) 
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SE11 Deployment of a live ECF vaccine in pastoral areas: lessons learned from Tanzania. 
 
Lynen et al. (2005). 
SE12 The use of a 30% formulation of oxytetracycline long-acting in East Coast Fever immunisation in Tanzania. 
 
Lynen et al. (unpublished data). 
SE13 Use of two different dose rates of oxytetracycline in East Coast fever immunisation in Tanzania Di Giulio et al. 
 
SE14 Technical meeting on the Infection and Treatment Method of East Coast Fever immunization and the way 
forward in Kenya. 
 
Turasha (2005) 
SE15 Molecular and immunological characterization of Theileria parva stocks which are components of the ‘Muguga 
cocktail’ used for vaccination against East Coast fever in cattle. 
 
Bishop et al. (2001) 
SE16 The biological and practical significance of antigenic variability in protective T cell responses against Theileria 
parva. 
 
Morrison (2007). 
SE17 Current status of vaccine development against Theileria parasites. 
 
Morrison and McKeever (2006). 
SE18 East Coast fever: 
1. Chemoprophylactic immunization of cattle against Theileria parva (Muguga) and five Theilerial strains. 
2. Cross-immunity trials with a Kenya strain of Theileria lawrencei. 
3. Chemoprophylactic immunization of cattle using oxytetracycline and a combination of theilerial strains. 
Radley et al. (1975a; b; c). 
SE19 Pharmacokinetics of two long-acting oxytetracycline products administered subcutaneously and intramuscularly  
 
Clarke et al. (1999). 
SE20 Perception of cattle farmers of the efficacy of East Coast fever immunization in Southern Zambia.   (Fandamu et al. 2006). 
 
SE21 Financial analysis of East Coast fever control strategies in traditionally managed Sanga cattle in central province 
of Zambia. 
 
Minjauw et al. (1999). 
SE22 Epidemiological aspects and economic impact of bovine theileriosis (East Coast fever) and its control: A 
preliminary assessment with special reference to Kibaha district, Tanzania. 
 
Kivaria et al. (2007). 
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Table 5.  Relationship of individual reports to specific issues of safety and efficacy 
 
Safety / efficacy parameter Report no. 
 
 
Safety  
(lack of significant adverse local or systemic reactions) 
 
Single dose 
 
SE1, SE2, SE3 
Repeated dose 
 
No data, see text 
Overdose 
 
SE1, SE4 
Live vaccines – reversion, shed and spread, dissemination 
 
SE5, SE6, SE7, SE15 
Field safety 
 
SE9, SE10, SE11, SE12, SE14 
Pregnancy and lactation 
 
No data, see text 
 
Efficacy 
(Evidence of protection compared to controls) 
 
 
Experimental challenge 
 
SE1, SE4, SE12 
Seroconversion (immunogenicity) 
 
SE2, SE3, SE8, SE12 
Dose determination 
 
SE1, SE4 
Onset of immunity 
 
SE2, SE3, SE5, SE8 
Duration of immunity 
 
SE5, SE17 
Field efficacy 
 
SE9, SE10, SE11, SE14 
General safety and efficacy summary SE16, SE17 
Safety and efficacy of oxytetracycline LA SE1, SE2, SE3, SE4, SE8, SE10, 
SE12, SE13, SE18, SE19 
Economic benefit / acceptance SE20, SE21, SE22 
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Safety  
 
Safety of a single dose.  Study SE1 (Mutugi et al., 1997) describes the three-stage process 
which was used to determine the safe and protective dose of batch FAO-1.  The investigation 
was done in three titration stages, with each stage consisting of immunization with the vaccine 
stabilate with oxytetracycline, followed after five weeks with a challenge with live sporozoites. 
The experimental design allowed the results from the first titration to form the basis for 
planning the second titration stage, which in turn led to planning and execution of the third and 
final titration step with the derivation of the recommended immunizing dose for the vaccine.   
A total of 72 cattle received varying dilutions of batch FAO-1 from ‘concentrated’ to 1:1024, 
along with oxytetracycline LA at 20 mg/kg.  A dose of 1:80 was found to be safe in terms of 
survival and relatively few reactions to vaccination.  This report provides evidence of safety of 
the selected dose 1:80 of the FAO-1 stabilate. Indeed the methodology described in the report 
was adopted as the method by which the safe and effective dose (dilution) was experimentally 
selected during manufacture of all subsequent batches. 
  
In study SE2 (Anon 1998), cattle were immunised with either a 1:80 or 1:100 dilution of FAO-
1 along with oxytetracycline LA at 30 mg/kg.  Animals were monitored for clinical reactions, 
rectal temperature and lymph node swelling.  Serum samples were taken on days 0 and 30 
for serology.  The results are summarised in Table 6. 
 
 
Table 6. Effect of 1:80 and 1:100 dilutions of batch FAO-1 ECF ITM MC (Anon, 1998) 
 
Group A B 
 
Number of animals 63 62 
Vaccine dilution 1:80 1:100 
Percent seroconverted day 0 13.6 18.3 
Percent seroconverted day 30 93.9 84.0 
Number with transient elevated 
rectal temperatures 
4 3 
Number with lymph node 
swellings 
10 31 
 
Elevations in rectal temperature were only slight and transient.  Lymph node swellings were 
only slight.  This study showed that the 1:80 and 1:100 dilutions of FAO-1 were safe and 
produced a high proportion of seroconversions in cattle after 30 days. 
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In study SE3 (Anon, 1999b) two groups of T. parva – seronegative cattle aged 4 to 10 months 
were immunised with a 1:80 dilution of either FAO-1 (GR5; n=31) or FAO-2 (GR7; n=31).  A 
high rate of seroconversion occurred by day 45 in both groups (see Table 7).  There were 
negligible clinical reactions to the vaccine in either group. 
 
Table 7. Effect of 1:80 dilutions of either batch FAO-1 or FAO-2 (Anon, 1999) 
 
Group Number of 
cattle 
Vaccine Percent 
seroconverted 
Number of 
reactions 
GR7 31 FAO-2 95 0 
GR5 31 FAO-1 100 1 
 
This study demonstrated the safety of both FAO-1 and FAO-2 at a dilution of 1:80 in 
conjunction with oxytetracycline LA at 30mg/kg.  The above three studies (SE1, 2 and 3) were 
taken together to confirm that a dilution of 1:80 is safe to the target animal. 
 
Safety of a repeated dose.  There did not appear to be any published reports of 
administration of repeated doses of MC to cattle.  This is primarily because a single dose of 
the vaccine is believed to provide life-long immunity, so there is no practical reason to repeat 
the immunisation.  However, it was argued in the dossier that there was no reason to assume 
that a repeated dose would be harmful.  Nevertheless, the importance of identifying vaccinated 
cattle by the recommended ear tagging procedure, as described in the SPC to avoid the 
possibility of repeat vaccination, was emphasised. 
 
Safety of an overdose (SE1 and SE4).  In study SE1 (Mutugi et al., 1997), the three stage 
titration study cattle received doses between ‘concentrated’ and 1:1024.  Although there were 
severe reactions and deaths at higher concentrations there were no such reactions or deaths 
at dilutions greater than 1:32. In study SE4 (ILRI, 1996), four groups each of two cattle 
received dilutions of batch FAO-1 at 1:10, 1:20, 1:40 and 1:80 respectively, together with 
oxytetracycline LA at 20 mg/kg.  The immunised cattle showed some elevation in rectal 
temperatures and evidence of parasitosis but none were severe and all recovered and 
seroconverted.   Although this study only included two animals per group, doses of FAO-1 as 
high as 1:10 were found to be safe in all animals.  Assuming a standard dose of FAO-1 is a 
1:80 dilution, then it was concluded that the above two studies (SE1 and SE4) show that the 
vaccine is safe at least at double that concentration and probably higher. 
 
Live vaccines – reversion, shed and spread (SE 5, 6 and 7).  Since the ITM vaccine is a 
formulation of virulent parasites, reversion to virulence is not appropriate for this product as it 
is known to be already highly virulent in susceptible cattle. 
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With regard to shed and spread, three studies were cited which examined the persistence of 
the vaccine strains in vaccinated cattle.   
 
In study SE5 (Oura et al., 2004), Kiambu 5 (K5) stock was found to behave quite differently 
from Muguga (M) or Serengeti transformed (ST) stocks.  K5 persisted in vaccinated cattle for 
up to two years while M and ST had been largely eliminated by 3 months.  There was little 
evidence of transmission to in-contact unvaccinated animals over a 1-year period.  Similarly, 
study SE6 (Oura et al., 2007) showed that K5 persisted in vaccinated cattle for up to 4 years.  
Bishop et al. (2001) SE15 had undertaken molecular characterisation studies confirming that 
K5 is quite distinct from the other two stocks which appear to be closely related.  These 
conclusions have more recently been confirmed by more detailed genomic studies (Norling et 
al., 2015; Hemmink et al., 2016), which suggest that the ST stock may have become 
contaminated with the Muguga one. 
 
Study SE7 (DeDeken et al., 2007) describes the investigation of a new clinical syndrome on 
Grand Comore.  The disease was identified as ECF, which had not previously occurred there 
with such severity.  Molecular characterisation revealed profiles identical to Muguga and 
Kiambu stocks of the Muguga cocktail.  R. appendiculatus was also found, which had hitherto 
not been present on Grand Comore.  The outbreak had occurred shortly after illegal 
importation of cattle from Tanzania.  The cattle were not tagged as is required after ECF-ITM 
administration.  It is apparent that this severe outbreak of ECF was due at least in part, to 
shedding of the Muguga  (± ST) and K5 parasites from ITM vaccinated cattle.  Therefore it is 
also apparent that vaccinated animals can shed both of these stocks.  This is somewhat in 
contrast to the findings of Oura et al. (2004, 2007; see above).  It is likely that the cattle on 
Grand Comore were more susceptible to these stocks than the Ugandan cattle investigated 
in Oura’s work.  In addition to suggesting that vaccinated cattle can transmit the parasite to 
uninfected cattle in non-endemic areas, this study (De Deken et al., 2007) underlines the 
importance of correct tagging of ITM-vaccinated animals.   
 
Thus the evidence concerning transmission from vaccinates to non-vaccinates was found to 
be equivocal and it was argued in the dossier that this may depend on innate immunity of the 
in-contact animals.  Therefore it was recommended in the SPC that extreme care should be 
exercised when co-mingling vaccinates and non-vaccinated animals, particularly those which 
may be naive / very susceptible to the MC stocks. 
 
Field safety (SE9, 10, 11, 12, 14).  In study SE9 (Magwisha et al., 2006) a total of 1,216 
cattle from 4 regions in Tanzania, immunised with MC about one year previously, were 
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sampled for serum T. parva antibody levels.  During this process a sample of farmers were 
questioned about their opinion of safety and efficacy of the vaccine.  A very high proportion 
indicated that there had been few clinical problems after use of the vaccine in their cattle.  
This is taken as anecdotal evidence of safety of the vaccine in the field.  
 
Study SE10 (Anon, 2007) is an update of field use of ECF-ITM between 1998 and 2007 in 
Tanzania and reported that 278,677 cattle had been immunised over that period.  It was 
concluded that the product was well accepted there as safe and efficacious. 
 
Study SE11 (Lynen et al., 2005) reported two trials carried out in pastoral areas of Tanzania.  
In the first study 110 calves aged between 2 and 6 months were either vaccinated (n=50) or 
not (n=50).  All animals were monitored for a period of 16 months.  In the second study a total 
of 1038 animals were included in the trial but the relative numbers of vaccinated and non-
vaccinated are not specified.  The results are shown in Table 8.  In summary there are highly 
significant reductions in mortality in vaccinated animals in both studies. 
 
 
Table 8.  The effect of ECF ITM MC in field studies in Tanzania (Lynen et al., 2005) 
 
Location Treatment Number of animals Mortality % 
Endulen  Vaccinated  50  4  
 
Controls  50  50      
Engare Naibor  Vaccinated   
1038 total  
2  
 
Controls  46  
 
 
It was reported that 80% of all mortalities in control cattle were due to ECF.  It was concluded 
that ECF-ITM (MC) is both safe and effective under field conditions in Tanzania. 
 
In study SE12 (Lynen et al., unpublished data), two experimental trials were carried out 
comparing the use of 30% oxytetracycline LA with 20% oxytetracycline LA.  Also the results 
of 1500 field immunisations are reported.  In the first experiment, 28 seronegative cattle were 
immunised with MC and 14 were given oxytetracycline LA 30% (Alamycin) at 30mg/kg and 14 
given a 20% oxytetracycline LA formulation (Coopertet) at 20mg/kg.  The animals were 
challenged with a live virulent preparation of homologous T. parva 45 days after immunisation.  
Five unvaccinated control animals were also challenged.  Two of the five controls died and 
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the other 3 developed chronic ECF.  There were no severe reactions in the 28 vaccinated 
animals but there was a significant difference in the percentage of mild reactors as shown in 
Table 9. 
 
In the second experiment, 104 seronegative dairy animals on farm were immunised with MC 
and half received each of the two oxytetracycline LA formulations.  There was a highly 
significant difference between the percentages of severe reactors in the two dose groups also 
shown in Table 9. 
 
Table 9.  The effect of oxytetracycline formulation and dose on safety of the 
Muguga cocktail 
 
Expt. Treatment Number Oxytetracyc. 
LA 
formulation 
Oxytetracyc. 
LA dose 
Percent 
mild 
reactors 
Number 
died 
1. Vaccinated 14 30% 30 mg/kg 7.1 0 
Vaccinated 14 20% 20 mg/kg 21.4 0 
Controls 5 - - 0 2 
       
2.     Percent severe 
reactors 
Vaccinated 52 30% 30mg/kg 7.4 
Vaccinated 52 20% 20mg/kg 44.0 
 
 
All vaccinated animals in the two experiments seroconverted following vaccination. 
 
Thirdly the experience of 1500 immunisations using oxytetracycline (Alamycin) 30% is 
reported.  It is stated that the number of immunisation reactors decreased from around 15% 
to less than 1% after the introduction of the 30% formulation.  Although some clinical reactions 
occurred which were described as severe, there were no mortalities and the proportion of 
severe reactions was clearly reduced by the use of oxytetracycline LA at 30mg/kg. 
 
In study SE14 (Turasha, 2005), 4000 cattle were immunised in Kenya, using oxytetracycline 
LA at 30 mg/kg.  Total reactions were 87 (2.2%) with a mortality of 46 (1.1%).  These figures 
are total mortality and not just that due to ECF and compare to historical mortality rates of 20-
40%.  This study demonstrates the safety and efficacy of MC under Kenyan field conditions. 
 
Safety in pregnancy and lactation. There were no available data on the use of ECF ITM MC 
in pregnant and lactating animals but in view of the many thousands of animals vaccinated 
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and the practice of whole herd vaccination, it was concluded that many pregnant and lactating 
animals must have been vaccinated in the field without reports of specific safety issues. 
 
Efficacy 
 
Experimental challenge (SE1, 4, 12). In SE1 (Mutugi et al., 1997) a three-stage titration study 
of the FAO-1 vaccine was carried out at the Vaccine Production Centre, Malawi between 
March and October 1997.  A total of 72 Friesian steers, aged between 6-9 months sourced 
from areas certified free of infectious diseases were used. Specifically, cattle used in the 
titration were negative for T. parva antibodies using both the IFAT and ELISA tests.  Each 
animal was inoculated subcutaneously with the appropriate dilution of the FAO-1 stabilate and 
treated simultaneously with oxytetracycline LA at 20 mg/kg bodyweight.  Immunized cattle 
were challenged using 1 ml of undiluted vaccine stabilate (a potentially lethal dose) 35 days 
after immunisation.  Susceptible cattle from the same batch were used as experimental 
controls.  
 
In the first titration pairs of cattle were inoculated with varying dilutions of the FAO-1 stabilate 
ranging from (1:2 to 1:1024 dilution). Results of the titration identified stabilate dilutions 
between 1:64 and 1:256 as the range within which broad protection was provided to cattle by 
the vaccine. The second stage focused on a narrower range of dilution for the optimal 
immunizing dose of between 1:60 and 1:100 of FAO-1 stabilate dilutions.  The third titration 
focused the investigation around the predicted optimal range of stabilate concentrations 
between 1:60 and 1:100 identified in stage two. The focus was three stabilate dilutions; (i) the 
predicted optimal immunizing dose (1:80) (ii) a dose more concentrated than the predicted 
optimal dose (1:100) in order to determine the safety margin of the vaccine, and (iii) a dilution 
that was less concentrated than the predicted optimal dose (1:60) to determine the vaccine 
efficacy. The optimal dose for the FAO-1 stabilate was found to be 1: 80 dilution.  This report 
provides direct evidence of efficacy of the selected dose 1:80 of the FAO-1 stabilate against 
experimental challenge. 
 
In study SE4 (ILRI, 1996) four groups each of two cattle received dilutions of FAO-1 at 1:10, 
1:20, 1:40 and 1:80 respectively together with oxytetracycline (Terramycin) LA 20% at 20 
mg/kg.  All animals plus two untreated controls received a homologous challenge a few weeks 
later.  The immunised cattle showed no clinical responses to challenge, with no pyrexia or 
schizonts detected.  The untreated controls reacted severely and were euthanized on days 13 
and 14 after challenge.  Although this study only included two animals per group, it 
demonstrated that dilutions of FAO-1 from 1:10 to 1:80 resulted in sero-conversion and 
protection against homologous challenge of all animals.  However only the 1:80 dilution result 
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was immediately relevant here as the other dilutions all represent higher doses than are used 
in the field. 
 
In study SE12 (Lynen et al., unpublished data), 28 seronegative cattle were immunised with 
MC and 14 were given oxytetracycline 30% (Alamycin) at 30 mg/kg and 14 given Coopertet a 
20% oxytetracycline LA formulation at 20 mg/kg.  The animals were challenged with a live 
virulent preparation of homologous T. parva 45 days after immunisation.  Five unvaccinated 
control animals were also challenged.  Two of the five controls died and the other 3 developed 
chronic ECF.  There were no severe reactions in the 28 vaccinated animals but there was a 
significant difference in the percentage of mild reactors as shown in Table 7.  This study 
provides further evidence of protection of vaccinated animals against experimental  
challenge with T. parva. 
 
Efficacy based on seroconversion (Immunogenicity; SE 2, 3, 8). Although it is believed 
that immunity to T. parva is due to cell mediated immune mechanisms (see Morrison, 2007 
SE16), seroconversion is widely accepted as an indirect indication of a protective response.  
This is based on the premise that animals which recover from T. parva infection are immune 
to subsequent disease and that seroconversion indicates prior infection. 
 
Study SE2 (Anon, 1998) was carried out at Mwanza, Tanzania starting in June 1998.  Cattle 
were immunised with either a 1:80 or 1:100 dilution of batch FAO-1.  Animals were monitored 
for clinical reactions, rectal temperature and lymph node swelling.  Serum samples were taken 
on days 0 and 30 for serology.  The results are summarised in Table 6.  This study shows that 
both the 1:80 and 1:100 dilutions of FAO-1 produce a high proportion of seroconversions in 
cattle after 30 days.  
 
In study SE3 (Anon, 1999) two groups of T. parva – seronegative Friesian x Ayrshire cattle 
aged 4 to 10 months were immunised with a 1:80 dilution of either FAO-1 (GR5; n=31) or 
FAO-2 (GR7; n=31), subcutaneously near to the parotid gland.  A high rate of seroconversion 
occurred by day 45 in both groups (see Table 7). 
 
Study SE8 (Anon, 1999a) examined the infectivity of FAO-1 stabilate after 2½ years storage 
at -200C at CTTBD, Lilongwe.  Three groups of 5 cattle were used.  They received either 1ml 
concentrated FAO-1 stabilate, 1ml of 1:80 dilution or 1ml 1:80 dilution plus oxytetracycline LA 
at 20 mg/kg bodyweight.  The results are shown in Table 10 below.  Serum from surviving 
cattle on days 28 and 35 showed high antibody titres to T. parva. 
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Table 10. Response of cattle to different concentrations of Muguga cocktail with or 
without oxytetracycline 
 
Number of cattle Treatment Mortality Time of death 
5 Concentrated stabilate 5/5 Before day 21 
5 1:80 dilution 4/5 Days 21-28 
5 1:80 dilution plus OTC 0/5 - 
 
 
Dose determination (SE1, 4). The two studies cited (Mutugi et al., 1997; ILRI, 1996) where 
dose determination was carried out have been reviewed above.  A dilution of 1:80 was found 
to be an effective dose. 
 
Onset of immunity (SE2, 3, 5, 8). Sero-conversion in cattle immunised with MC had 
occurred by 30 days (SE2, Anon, 1998), 45 days (SE3, Anon, 1999) 48 days (SE5, Oura et 
al., 2004)) and 28-35 days (SE8, Anon, 1999).  Thus it was concluded that onset of immunity 
occurs within 28-30 days after immunisation.  There are earlier studies which support this 
conclusion which are indicated in the Discussion. 
 
Duration of immunity (SE5, SE17). We could find no data on duration of immunity beyond 
the presence of specific antibodies at day 48 (SE5, Oura et al., 2004).  However it is generally 
accepted that ECF-ITM produces lifelong immunity in vaccinated cattle or at least for several 
years (see SE17; Morrison and McKeever, 2006).  Also there would be expected to be a 
‘trickle challenge’ by ticks in the field, particularly if the frequency of acaricide treatment is 
reduced after vaccination.  This would probably have the effect of continually boosting 
immunity to T. parva.  As discussed above, the vaccine stabilate persists in animals for some 
time after vaccination.  The lack of disease in these animals suggests the presence of a 
protective immune response.  For these reasons, it was argued in the dossier that immunity 
would last for several years and in the field it is generally held that immunity is effectively 
lifelong. 
 
Field efficacy (SE9, 10, 11, 14). In study SE9, (Magwisha et al., 2006) a total of 1216 cattle 
from 4 regions in Tanzania, immunised with MC about one year previously were sampled for 
serum T. parva antibody levels.  A value of 20 was taken as the threshold for sero-conversion.  
Overall 70.1% of the vaccinates and 46% of non-vaccinates had antibody levels above 20, 
suggesting protection against disease (see Table 11). 
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Table 11. Serum antibody responses of cattle approximately 1 year after 
vaccination with Muguga cocktail (Magwisha et al., 2006). 
 
Region Total number of 
animals 
Antibody titre <20 Antibody titre >20 
Number Percent Number Percent 
 
Arusha 225 153 68 72 32 
Coast 208 57 27 151 73 
Mara 311 56 18 255 82 
Morogoro 472 97 21 375 79 
 
Total / 
mean 
 
1216 
 
363 
 
29.9 
 
853 
 
70.1 
Controls 67 36 54 31 46 
 
 
In report SE10 (Anon, 2007), a total of 278,677 cattle had been immunised with ECF-ITM MC 
between 1998 and 2007.  It was concluded that there was a high degree of confidence in the 
procedure and that ECF-ITM is well accepted as a safe and efficacious product in Tanzania. 
 
Study SE11 (Lynen et al., 2005) comprised two field studies were carried out in pastoral areas 
of Tanzania, one in Endulen and one in Engare Naibor. In the first study 110 calves aged 
between 2 and 6 months were either vaccinated (n=50) or not (n=50).  All animals were 
monitored for a period of 16 months.  In the second study a total of 1038 animals were included 
in the trial but the relative numbers of vaccinated and non-vaccinated are not specified.  The 
results are shown in the Table 8.  In summary there are highly significant reductions in mortality 
in vaccinated animals in both studies.  80% of all mortalities in control cattle were due to ECF.  
It is concluded that ECF-ITM with Muguga cocktail is both safe and effective under field 
conditions in Tanzania. 
 
In study SE14 (Turasha, 2005), 4000 cattle were immunised and 30% oxytetracycline LA was 
used.  Total reactions were 87 (2.2%) with a mortality of 46 (1.1%).  These figures are total 
mortality and not just that due to ECF and compare to historical mortality rates of 20-40%.  
This report demonstrates the safety and efficacy of Muguga cocktail under Kenyan field 
conditions. 
 
It is concluded that the above four reports provide good evidence of the efficacy of ECF-ITM 
MC under field conditions. 
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Further support for the general safety and efficacy of the product are provided in SE16 and 
17 (Morrison 2007; Morrison and McKeever, 2006). 
 
Safety and efficacy of oxytetracycline 
 
Since ITM is a live, virulent vaccine, concurrent treatment with oxytetracycline long acting (LA) 
is necessary to reduce severe clinical signs and even death after vaccination.  However the 
concentration and dose of oxytetracycline has been the subject of some debate.  The 
publications of Radley et al. (1975a, b, c; SE18) were amongst the first to describe the use of 
oxytetracycline, but preceded the availability of an LA formulation and therefore used a series 
of daily injections.  When the first LA formulation became available, it was used at a dose rate 
of 20 mg/kg.  Indeed it is apparent that it was used at this dose in a series of studies including 
the titration of the FAO-1 batch to determine the optimal therapeutic dose (SE1, Mutugi et al., 
1997; SE4, ILRI, 1996; SE3, Anon 1999).  However it became apparent from field reports that 
on occasion, the frequency and severity of adverse clinical reactions to immunisation were 
unacceptably high.  Higher dose rates were used e.g. 30 mg/kg but with the 20% formulations 
available, the injection volume was often very large in heavier cattle.  The availability of a 30% 
formulation was welcomed and was shown to be preferable in terms of reducing the frequency 
and severity of clinical reactions when used at 30 mg/kg as opposed to 20% at 20 mg/kg 
(SE10, Anon, 2007; SE12 Lynen et al., unpublished data).  Unfortunately these studies were 
somewhat confounded by using a different dose per unit-bodyweight as well as a different 
formulation.  Nevertheless other reports have concluded that the use of 30 mg/kg is preferable 
(SE2, Anon 1998; SE3, Anon 1999; SE14 Turasha 2005).   
 
Another confounding factor was that different studies used different brands of oxytetracycline 
LA.  Study SE19 (Clarke et al., 1999) compared the pharmacokinetics of two long-acting 
oxtetracycline preparations, manufactured by Merial and Boehringer Ingelheim respectively 
given at 20mg/kg by the subcutaneous or intramuscular route in Hereford steers.  Although 
there were marginal differences, the pharmacokinetics in all four situations were very similar 
and it was concluded that the two products were bio-equivalent.   Although not directly relevant 
to the use of oxytetracycline in East Africa this study demonstrated that two generic 
oxytetracycline preparations of equivalent concentrations (20%) exhibit similar 
pharmacokinetics and it is inferred that most available generic oxytetracycline LA products are 
formulated to exhibit similar pharmacokinetic profiles. 
 
Study SE13 (di Giulio et al. unpublished data) compared the same formulation (30%) 
oxytetracycline LA at 30 vs. 40 mg/kg and concluded that while reducing the number of 
reactions, the higher dose also resulted in fewer seroconversions to the vaccine.  Therefore it 
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was concluded that 30 mg/kg was the optimal dose for use with ECF-ITM and it is apparent 
that this is widely accepted. 
 
The dossier proposed that while very few brands of oxytetracycline LA had been directly 
evaluated for this indication experimentally, it should be administered at 30mg/kg in the 
vaccination programme.  If a lower dose of 20mg/kg is chosen then the vaccinated cattle 
should be more closely monitored for several days for signs of adverse reaction so that they 
can be further treated if necessary. 
 
 
Economic benefit 
 
Three studies were reviewed concerning the economic impact of ECF-ITM.  Study SE20 
(Fandamu et al., 2006) used a structured questionnaire to assess the perception of 179 cattle 
farmers of the efficacy of ECF-ITM vaccination in southern Zambia.  The majority (85%) 
regarded immunization as very effective and about half (51.4%) preferred immunization to 
other ECF control strategies.  The study showed that the number of calves immunized was 
strongly associated with the farmer’s perception of the benefits of immunization.  It is 
concluded that ITM is regarded as effective by the majority of farmers in the study. 
 
In study SE21 (Minjauw et al., 1999) the financial consequences of five different ECF control 
strategies were analysed as follows: 
• ECF immunisation and no tick control (INT) 
• ECF immunisation and seasonal treatment for ticks (IS) 
• ECF immunisation and weekly treatment for ticks (IW) 
• No ECF immunisation and weekly treatment for ticks (NIW) 
• No ECF immunization and no tick control (NINT) 
 
Input and output data were calculated to construct discounted cashflows for each group.  It 
was concluded that seasonal spraying with acaricide plus immunization (IS) gave the highest 
net present value and that no control (NINT) gave the lowest.  It was shown that ITM costs 
could rise to US$ 25.90 per head before profitability was affected.  Therefore ITM combined 
with seasonal tick control was the most cost effective measure to control ECF. 
 
Study SE22 (Kivaria et al., 2007) comprised a cross sectional study based on clinical 
examination, inspection of herd health records and a questionnaire designed to determine the 
epidemiology, economics and potential impact of immunization against theileriosis in 
Tanzania.  The results showed annual theileriosis costs to be US$ 205.40 per head, whereas 
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the introduction of immunization reduced this by 40-68% depending on the post-immunisation 
dipping strategy.  It was concluded that farmers who have immunized their cattle may 
cautiously reduce acaricide application by 50-75% depending on the level of tick challenge at 
the herd level.  It was concluded that ECF-ITM immunization can effectively reduce costs 
associated with theileriosis but should be combined with strategic acaricide treatment post-
immunisation. 
 
Taken together these studies it was concluded that there is economic benefit real and 
perceived in the field application of ECF-ITM. 
 
Benefit – risk analysis 
 
It was argued in conclusion that the following aspects had been demonstrated in the reports 
presented in this dossier: 
 
• The ECF-ITM MC vaccine as exemplified by batches FAO-1 and 2 is safe and effective 
at a final dilution of 1:80, when used according to instructions in the Summary of 
Product Characteristics (Product Data Sheet; see Appendix 1). 
 
• Whilst systemic clinical reactions can occur following vaccination, these can be 
minimised by the concurrent use of oxytetracycline LA at a dose of 30 mg/kg. 
 
• If oxytetracycline is given at 20 mg/kg then vaccinated animals should be monitored 
intensively for several days in case further anti-theilerial treatment is necessary. 
 
• Muguga cocktail should only be used in areas where epidemiological data indicate that 
Muguga, Serengeti transformed and Kiambu 5 stocks are appropriate for that region. 
 
• There is some evidence of differential shedding and transmission by the 3 stocks in 
MC.  Although evidence of clinical disease in in-contact non-vaccinates is equivocal 
every effort should be made to protect susceptible animals from close contact with 
newly vaccinated cattle. 
 
 
Dossier submission to national authorities 
 
Due to its large file size the dossier was prepared as a CD-Rom and multiple copies prepared 
for distribution to the agencies and individuals closely involved in the registration process.  In 
the case of Kenya, this was submitted by an academic consultant on behalf of GALVmed. For 
Tanzania a local technical representative (Drs Lynen and Di Giulio) was used in-country and 
for Malawi the dossier was submitted by the management of the CTTBD Lilongwe.  For 
Uganda an in-country technical representative was appointed to submit and negotiate 
approval of the dossier.  The registrations were processed by the respective competent 
authorities in the respective countries as shown in Table 12. 
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Table 12.  Details of ECF ITM MC dossier submission and review by national 
regulatory authorities 
 
 Dossier submitted 
by 
National regulatory ‘competent 
authority’ 
Registration granted 
Kenya Academic 
consultant 
Pharmacy and Poisons Board 2009 
Tanzania In-country 
technical 
representative 
Tanzania Food and Drugs 
Agency 
2009 
Malawi CTTBD 
management 
National Drug Authority 2008 
Uganda In-country 
technical 
representative 
Ministry of Health Not registered 
 
The registration process in Uganda was originally refused due to failure of GMP inspection by 
the Ugandan authorities, although this had been previously approved by PANVAC.  It became 
clear that national standards could vary substantially between countries and the need for 
closer regional harmonisation on regulatory issues was identified.  
 
Discussion 
 
This paper describes the process of assembly of the original dossier and the challenges which 
were faced during the registration of the ITM live vaccine. The product is an unusual vaccine 
whose target users are predominantly poor livestock owners in eastern, central and southern 
Africa.  The vaccine was manufactured by ILRI, an institute whose primary focus is research 
and not the production of commercial vaccines. These factors were taken into account when 
the registration was prepared, with an emphasis on ‘fitness for purpose’.  Subsequent sales 
of the vaccine established that, despite the limited geographical location of the disease, there 
is a high demand for the vaccine. Several issues emerged during the registration process, and 
these are discussed below. 
 
Definition of the composition of the vaccine was not straightforward, as the components were 
prepared from ill-defined field isolates prepared several years earlier.  Subsequent to the 
submission of the dossier, it was reported that that the component stabilates are composed of 
at least 14 different parasite types, based on genotypes established with satellite markers 
(Patel et al., 2011), although there is limited diversity in the satellite loci among the genotypes 
(Hemmink, 2016).  It has also been shown that the composition of the FAO batch from 1996 
and the ILRI-08 batch made in 2007 were very similar, suggesting that the manufacturing 
procedure provides consistency in the vaccine stabilate (Patel et al., 2011).  An additional 
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study showed that there is a remarkable degree of similarity in the genomic composition of 
two of the stabilates (Muguga and Serengeti-transformed) to the extent that it is now 
suspected that some contamination occurred during the several tick-cattle passages that 
preceded establishment of the current stabilates. 
 
A distinctive feature of the production process is the use of live animals, with the associated 
risks of inconsistent reactions and the introduction of extraneous pathogens into final vaccine 
stabilate.  To minimize these risks, the dossier included specifications of where the type of 
animals to be used and where they should be, and a series of tests to detect such pathogens.  
In addition, the dossier describes the extensive clinical and parasitological examinations which 
were undertaken to ensure the ticks are applied at the right time and that the level of infection 
of the ticks is correctly estimated. 
 
A key feature of the successful production of the ITM vaccine is the availability of suitable tick 
facilities and expertise in the biology of ticks.  Such facilities are not common and it is a major 
reason why ILRI was initially asked to produce the commercial-scale batches of the vaccine.  
It is clear that the primary purpose of tick facilities is to make possible research on ticks and 
tick-borne pathogens, and the dossier had to make allowance for this.  It is also a major 
challenge to the full privatization of the production and distribution of the ITM vaccine and 
other vaccines requiring a tick phase in the production process. 
 
Because of the otherwise lethal nature of the vaccine stabilate and the potential for variation 
in its quantitative and qualitative aspects, the paramount quality test on the finished product is 
the series infection and challenge experiments. The dossier contained the results of several 
such tests.  It is recognised that these are expensive and time-consuming, and are a 
consequence of the lack of a method for assessing the potency of the vaccine in vitro.  The 
most direct method would involve the counting of viable sporozoites. Such a method does not 
currently exist, due in part to the tendency of sporozoites to form aggregates. DNA-based 
methods do not distinguish between live and dead parasites.   A simple estimation of the 
number of sporozoites would also fail to allow for variations in the virulence and antigenic 
specificity of the parasites. Until such methodology is developed, registration of each batch of 
the vaccine will rely of the data from such trials, although it is hoped the accumulating 
experience with production will reduce the number of iterations of the experiment.      
 
It is questionable how accurately the immunization and challenge experiments can discern a 
difference in clinical reactions or protection between dilutions of, say, 1:60 and 1:80.    The 
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variability in response of individual animals and the need to limit the number of animals in any 
experiment, suggest that there is likely to be as much variation within a dosage group as there 
is between groups.  The dosage which was finally recommended is a balance between one 
which is clearly safe and clearly effective. 
  
The European dossier format used as a template for the current submission requires several 
other post production tests, such as stability, for which no tests were available.   In lieu of 
these, the dossier presented evidence from published articles and field reports to articulate 
support the various claims.  These are supported by additional publications which were not 
included in the dossier.  For example, Morzaria et al. (1997) showed that animals could survive 
an otherwise lethal challenge as soon as five days after immunization.  With regard to the 
duration of immunity, Burridge et al. (1972) reported that animals that had recovered from 
infection with the T. parva (Muguga) stabilate and kept under ECF-free conditions were 
protected against lethal homologous challenge up to 43 months following the initial infection. 
 
In recent years regulatory systems for veterinary medicines in East African countries have 
developed considerably including a mutual recognition system for vaccines.  This has 
happened at least in part due to the investment by the Bill and Melinda Gates Foundation 
through funding of agencies such as the Global Alliance for Livestock Veterinary Medicines 
(GALVmed).  This has considerably improved the process of veterinary medicine registration 
in the region. 
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Appendix 1 
 
Summary of product characteristics (Product Data Sheet) 
 
East Coast Fever – Infection & Treatment Method (Muguga cocktail) 
 
Composition 
This is a live East Coast Fever (ECF) vaccine produced from 3 Theileria parva stocks: T. parva 
Muguga, Kiambu 5 and Serengeti-tranformed. The parasites are suspended in Eagle’s 
Minimum Essential Medium, which contains 3.5% bovine serum albumin (Fraction V), 7.5% 
glycerol to protect the parasites during freezing and thawing, penicillin (150 units/ml) and 
streptomycin (150 µg/ml). 
 
Presentation 
The vaccine is presented as: 
• Concentrated Vaccine Stabilate in coloured 0.5ml straws sealed at one end. 
• Vaccine Stabilate Diluent in glass serum bottles containing the required volume for 
dilution of VS (following the procedure described below). The bottles are closed with 
grey butyl rubber stoppers and sealed with aluminium tear-off seals. 
 
On thawing the concentrated VS is an opaque dark brown finely particulate suspension. As a 
consequence upon thawing the VS should be carefully mixed, but without shaking, before 
addition to the VS diluent.  Dilution of concentrated VS to provide the immunisation dose 
provides a light orange-brown solution, finely particulate. 
 
Pharmacological Action 
Immunisation with the vaccine allows the controlled establishment of the 3 component parasite 
stocks in cattle.  Overt disease is prevented by simultaneous treatment with oxytetracycline. 
Immunised cattle develop full immunity within 4 weeks to the component- and 
immunologically- related stocks of T. parva. 
 
Indications 
The ECF vaccine is indicated in the following situations: 
• For Bos indicus calves in ECF endemic areas. It can be used safely in calves over 1 
month of age. 
• For pure and cross-bred cattle susceptible to ECF in endemic areas, or for cattle to be 
moved to endemic areas. 
• Other cattle not immune to ECF. 
  
The vaccine will not protect against theileriosis caused by Theileria annulata or Theileria 
mutans. 
 
 
Contra-indications 
Cattle should not be immunised with this vaccine in the following circumstances: 
• Cattle incubating or showing symptoms of ECF. These cattle should be treated with 
anti-theilerial drugs e.g. Butalex. 
• Calves less than 1 month of age. 
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• Cattle in poor condition and or suffering from other disease, especially those 
undergoing infection with Foot and Mouth Disease or Lumpy Skin Disease. There is a 
risk of adverse ECF immunisation reactions in these cattle. 
• Cattle in the last 3 months of pregnancy. 
• Cattle treated with levamisole within one month of planned immunisation. There is a 
risk of ECF immunisation reactions in these cattle. 
• Cattle in draught work. 
 
Storage and handling of the vaccine 
• Vaccine Stabilate concentrate must be kept frozen in liquid nitrogen until immediately 
before use. 
• Vaccine Stabilate diluent must be kept frozen below -20C until required for dilution of 
Vaccine Stabilate concentrate. Refer to details below. 
• In the field, the Vaccine Stabilate diluent must be kept in a coolbox on ice, but not 
submerged in ice/water.  
 
Directions for use – Vaccine Stabilate dilution and immunisation procedure 
 
Thawing, dilution and handling of Vaccine Stabilate and diluent 
(a) Vaccine Diluent 
Thaw the diluent using warm water, as necessary, but below 40oC, taking care to avoid 
immersing the bottle cap, since water may enter the bottle. Carefully mix the diluent 
bottle during thawing, but do not shake to avoid frothing. Check to ensure the diluent 
is completely thawed, dry the bottle and place immediately on ice. The temperature of 
the diluent during this process should not rise above about 10oC.  
 
Do not use thawed diluent if colour is deep red or bright yellow. 
Once thawed, unused diluent should not be frozen and re-used. 
 
(b) Vaccine Stabilate concentrate 
 
1. Take out the number of straws required (bearing in mind time available to immunise 
with the prepared vaccine is 2 hours - 4 hours) and the number of diluent bottles 
to be used (1 straw = 32 doses of current Vaccine Stabilate – minus handling 
losses). Thaw the straws by rolling them in between palms for 1-2 minutes.  Normal 
safety precautions should be observed in handling liquid nitrogen. 
 
2. Remove the contents of the straw into a pre-cooled sterile serum tube e.g. Nunc 2 
ml tube. If 2 or more straws are to be used it is advisable to pool the straw contents. 
 
3. Draw 0.4 ml of Vaccine Stabilate concentrate into a 1 ml syringe, and inject into 
one diluent bottle, but firstly drawing some diluent into this syringe, allowing for 
mixing of diluent and stabilate and injecting the mixture into the diluent bottle. This 
process should be repeated to ensure that the full volume of Vaccine Stabilate has 
been transferred. Keep diluent bottle inverted during this mixing to avoid air 
bubbles and frothing of the diluent bottle contents. 
 
4. Put prepared vaccine on ice in a suitable cool box, it can now last for 2 hours, with 
4 hours maximum under optimal conditions. Do not allow cap of bottle to come into 
contact with or be immersed in ice-water. 
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5. Do not use prepared vaccine if colour is deep red or bright yellow. Normal colour 
should be in the range orange-red to orange-yellow. 
 
6. Mix the prepared vaccine gently and avoid shaking the vaccine bottle as this will 
cause foam and loss of usable vaccine volume. Draw 1 ml of prepared vaccine in 
a suitable 1ml syringe from the diluent bottle and inoculate immediately as above. 
Return the vaccine bottle to storage on ice as quickly as possible. Do not fill the 
syringe unless the animal can be inoculated immediately, as keeping the filled 
syringe in the environment can result in deterioration of the vaccine.  
 
 Immunisation procedure 
 
1. Tag the animal and record the number. 
 
2. Weigh the animal and record the weight. 
 
3. Injection of long acting oxtetracycline (OTC) 30% (1 ml/ 10 Kg), volumes of drug 
exceeding 15 ml should be injected in different sites, calves below 50 kg receive a 
standard 5 ml dose. 
 
4. Inject 1 ml of prepared Vaccine Stabilate, diluted as below, subcutaneously close to 
the parotid gland (i.e. slightly below and in front of the base of the ear). Use this 
opportunity to check for possible gland swelling due to ECF and if detected do not 
immunise, but treat with anti-theilerial drugs e.g. Butalex. 
 
5. Monitor the animals for 10-20 minutes after immunisation in order to observe possible 
allergic reaction (skin rash, lacrimation, salivation, swollen eyelids, rapid breathing). If 
severe allergic reactors are observed treat the animal with 2-4 ml of adrenaline (1:1000 
dilution). 
 
6. Monitor animals after immunisation in close collaboration with the livestock owner. 
Animals showing severe signs of ECF 2-3 weeks after immunisation must be treated 
with anti-theilerial drugs. 
 
Note: Any stabilate left after the last animal has been immunised must be discarded. 
 
 
Safety (adverse reactions in cattle to immunisation) 
The VS has been thoroughly tested in large numbers of cattle before release to provide a safe 
immunising dose. The use of 30mg/Kg OTC has been shown to eliminate or minimise 
untoward reactions in cattle. 
 
The vaccine supplier/immunising team will instruct livestock owners about monitoring of 
immunised cattle and on the action to take in the rare case of an adverse reaction to 
immunisation, as follows: 
 
o Cattle should be monitored for 10-20 minutes after immunisation in order to observe 
possible allergic reactions 
• These could include: skin rash, lacrimation, salivation, swollen eyelids.  
• If severe allergic reactors are observed cattle should be treated with 2-4 ml of 
adrenaline (1:1000 dilution). 
 36 
 
o Cattle should also be monitored for 2-3 weeks following immunisation in close 
collaboration with the livestock owner. Animals showing severe signs of ECF must be 
treated with anti-theilerial drugs e.g. Butalex ® 
 
 
Operator safety 
Humans are not at risk of infection with ECF. 
 
 
Efficacy 
The trivalent live ECF vaccine will protect cattle against field challenge from a wide range 
of Theileria parva stocks, but the possibility of unknown and different immunogenic stocks 
breaking through this immunity cannot be excluded. 
 
It has also been demonstrated to protect cattle in areas with presence of African buffalo, 
such as in Northern Tanzania and in the Loita District of Kenya. However, the vaccine may 
not protect against all Theileria parva stocks derived from buffalo. 
 
 
Additional precautions 
Oxytetracycline (OTC) brands for immunisation 
 
The brand and concentration of OTC administered as treatment during immunisation can 
influence the response of cattle to immunisation and therefore the quality of the immune 
response. Only approved brands and drug concentrations should be used during 
immunisation. 
 
At present only one brand and dose of OTC has been evaluated for use with this vaccine. 
Certain other OTC brands and doses have been used with different vaccines, but the 
determination of the Vaccine Stabilate dose to provide safe and protective immunisation has 
only been carried out with one brand of OTC.  
 
 
Warnings 
• Standard safety precautions must be followed for the handling of liquid nitrogen. 
• This vaccine may lose efficacy if the conditions for handling as described above are 
not followed precisely. 
 
 
Manufacturer and distributor details 
TBD 
 
 
___________________ 
 
